Drug Delivery

Eli Lilly launches citrate-free Taltz formulation

Eli Lilly and Company has announced that its Taltz (ixekizumab) 80mg/mL injection is now available in a new, citrate-free formulation.

Bavarian Nordic to supply additional monkeypox vaccine doses to US

Bavarian Nordic has received an order from the US Biomedical Advanced Research and Development Authority (BARDA) for additional doses of Jynneos, a non-replicating vaccine against smallpox and monkeypox.

US buys additional Bavarian Nordic’s smallpox and monkeypox vaccine doses

The US Biomedical Advanced Research and Development Authority (BARDA) has ordered additional doses of Bavarian Nordic’s Jynneos, a non-replicating vaccine to prevent smallpox and monkeypox.

Axsome Therapeutics signs agreement for Sunosi acquisition

Biopharmaceutical firm Axsome Therapeutics has signed a definitive agreement with Jazz Pharmaceuticals to acquire Sunosi (solriamfetol), in a deal valued at $53m.

Altamira, Nuance Pharma sign distribution deal for Bentrio in Asian markets

Altamira Therapeutics has signed an exclusive licensing and distribution agreement with Nuance Pharma for its nasal spray, Bentrio (AM-301), in Chinese Mainland, Hong Kong, Macau and South Korea.

Merck, Ridgeback to supply 1.75 million molnupiravir courses to UK

Merck and its partner Ridgeback Biotherapeutics have received an order from the UK Government to supply an additional 1.75 million patient courses of investigational Covid-19 oral antiviral drug molnupiravir (MK-4482).

Allergan announces availability of VUITY in US pharmacies

AbbVie’s subsidiary Allergan has announced the availability of FDA-approved eye drop, VUITY (pilocarpine HCl ophthalmic solution) 1.25%, by prescription in pharmacies across the US.

Pfizer secures US contract to supply Covid-19 oral antiviral drug courses

Pfizer has secured a contract worth $5.29bn from the US government to supply its experimental Covid-19 oral antiviral drug, Paxlovid (PF-07321332; ritonavir).

GSK and Vir to supply Covid-19 antibody treatment doses to US

GlaxoSmithKline (GSK) and Vir Biotechnology have secured contracts from the US government for nearly $1bn to supply their Covid-19 antibody treatment, sotrovimab.